| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 12,770 | 16,856 | 15,088 | 19,703 |
| Investment securities | 210,053 | 202,989 | 190,882 | 196,573 |
| Prepaid expenses and other current assets | 4,226 | 3,939 | 3,059 | 3,518 |
| Total current assets | 227,049 | 223,784 | 209,029 | 219,794 |
| Property and equipment | 3,245 | 3,245 | 3,212 | NaN |
| Less accumulated depreciation | 2,421 | 2,264 | 2,108 | NaN |
| Other assets | NaN | 0 | 0 | 0 |
| Property and equipment, net | 824 | 981 | 1,104 | 1,258 |
| Right-of-use asset | 2,569 | 1,438 | 1,637 | 1,834 |
| Total assets | 230,442 | 226,203 | 211,770 | 222,886 |
| Accounts payable | 2,276 | 2,312 | 1,913 | 1,013 |
| Accrued expenses and other current liabilities (including related party amounts of 890 as of december 31, 2025) | 7,914 | 10,743 | 9,260 | 7,734 |
| Total current liabilities | 10,190 | 13,055 | 11,173 | 8,747 |
| Operating lease liability | 2,198 | 645 | 877 | 1,102 |
| Total liabilities | 12,388 | 13,700 | 12,050 | 9,849 |
| Common stock, 0.0001 par value 200,000,000 shares authorized at march 31, 2026 and december 31, 2025 62,441,429 and 60,398,051 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 6 | 6 | 6 | 6 |
| Additional paid-in capital | 532,958 | 509,100 | 480,365 | 476,738 |
| Accumulated deficit | -314,642 | -297,006 | -281,009 | -264,012 |
| Accumulated other comprehensive income | -268 | 403 | 358 | 305 |
| Total stockholders' equity | 218,054 | 212,503 | 199,720 | 213,037 |
| Total liabilities and stockholders' equity | 230,442 | 226,203 | 211,770 | 222,886 |
Design Therapeutics, Inc. (DSGN)
Design Therapeutics, Inc. (DSGN)